532. Nirmatrelvir/Ritonavir Versus Placebo in Unvaccinated and Vaccinated High Risk Patients

BACKGROUND: Nirmatrelvir with ritonavir (nirmatrelvir/r) is an oral antiviral treatment for COVID-19. EPIC-high risk (HR) was a Ph 2/3 double-blind, randomized, placebo (PBO)-controlled trial to evaluate nirmatrelvir/r in symptomatic, unvaccinated, nonhospitalized patients (pts) with ≥ 1 risk factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Leister-Tebbe, Heidi, Bao, Weihang, Fountaine, Robert, Baniecki, Mary Lynn, Hendrick, Victoria, Wisemandle, Wayne, Hammond, Jennifer, Rusnak, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677571/
http://dx.doi.org/10.1093/ofid/ofad500.601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677571/
http://dx.doi.org/10.1093/ofid/ofad500.601

Ejemplares similares